Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free HSAQ Stock Alerts

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

Health Sciences Acquisitions Co. 2 logo
$4.01 -0.01 (-0.25%)
As of 05/5/2026
Compare

HSAQ vs. NSPR, TMDIF, PETV, RVP, and BTCY

Should you be buying Health Sciences Acquisitions Co. 2 stock or one of its competitors? The main competitors of Health Sciences Acquisitions Co. 2 include InspireMD (NSPR), Titan Medical (TMDIF), PetVivo (PETV), Retractable Technologies (RVP), and Biotricity (BTCY). These companies are all part of the "surgical & medical instruments" industry.

How does Health Sciences Acquisitions Co. 2 compare to InspireMD?

InspireMD (NYSE:NSPR) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

44.8% of InspireMD shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 34.1% of InspireMD shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

InspireMD presently has a consensus price target of $4.50, indicating a potential upside of 287.93%. Given InspireMD's stronger consensus rating and higher possible upside, equities research analysts clearly believe InspireMD is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InspireMD
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, InspireMD had 12 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 12 mentions for InspireMD and 0 mentions for Health Sciences Acquisitions Co. 2. InspireMD's average media sentiment score of 0.22 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that InspireMD is being referred to more favorably in the media.

Company Overall Sentiment
InspireMD Neutral
Health Sciences Acquisitions Co. 2 Neutral

InspireMD has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than InspireMD.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InspireMD$10.85M5.01-$19.92M-$0.73N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat InspireMD's return on equity.

Company Net Margins Return on Equity Return on Assets
InspireMD-413.96% -69.42% -57.68%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Summary

InspireMD beats Health Sciences Acquisitions Co. 2 on 8 of the 13 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Titan Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Titan MedicalN/A -82.31% -51.47%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Titan Medical had 1 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 1 mentions for Titan Medical and 0 mentions for Health Sciences Acquisitions Co. 2. Titan Medical's average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company Overall Sentiment
Titan Medical Neutral
Health Sciences Acquisitions Co. 2 Neutral

Titan Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500.

Titan Medical has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Titan Medical$17.63M1.84$6.95M$0.055.68
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

Summary

Titan Medical and Health Sciences Acquisitions Co. 2 tied by winning 4 of the 8 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to PetVivo?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat PetVivo's return on equity.

Company Net Margins Return on Equity Return on Assets
Health Sciences Acquisitions Co. 2N/A N/A -2.38%
PetVivo -902.82%-4,813.07%-281.78%

Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, PetVivo has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

In the previous week, Health Sciences Acquisitions Co. 2's average media sentiment score of 0.00 equaled PetVivo'saverage media sentiment score.

Company Overall Sentiment
Health Sciences Acquisitions Co. 2 Neutral
PetVivo Neutral

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Comparatively, 10.8% of PetVivo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than PetVivo.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A
PetVivo$1.05M26.75-$10.95M-$0.38N/A

Summary

Health Sciences Acquisitions Co. 2 beats PetVivo on 6 of the 8 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Retractable Technologies' net margin of -41.11%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Retractable Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Retractable Technologies-41.11% -17.15% -9.33%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Retractable Technologies had 1 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 1 mentions for Retractable Technologies and 0 mentions for Health Sciences Acquisitions Co. 2. Retractable Technologies' average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company Overall Sentiment
Retractable Technologies Neutral
Health Sciences Acquisitions Co. 2 Neutral

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Retractable Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Retractable Technologies$38.27M0.55-$7.01M-$0.42N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

Retractable Technologies has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500.

Summary

Health Sciences Acquisitions Co. 2 beats Retractable Technologies on 5 of the 9 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Biotricity?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Biotricity's net margin of -80.42%.

Company Net Margins Return on Equity Return on Assets
Health Sciences Acquisitions Co. 2N/A N/A -2.38%
Biotricity -80.42%N/A -188.47%

In the previous week, Health Sciences Acquisitions Co. 2's average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score.

Company Overall Sentiment
Health Sciences Acquisitions Co. 2 Neutral
Biotricity Neutral

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Biotricity.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A
Biotricity$12.06M0.62-$14.09M-$0.16N/A

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Comparatively, 10.1% of Biotricity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Health Sciences Acquisitions Co. 2 beats Biotricity on 5 of the 7 factors compared between the two stocks.

Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically

Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HSAQ vs. The Competition

Export
MetricHealth Sciences Acquisitions Co. 2Surgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$44.96M$47.77M$6.30B$12.15B
Dividend YieldN/A1.08%2.77%5.24%
P/E RatioN/A15.8728.7027.01
Price / SalesN/A30.28528.9177.57
Price / CashN/A18.8843.3053.97
Price / Book-6.4714.539.866.89
Net Income-$380K-$20.10M$3.55B$333.11M
7 Day PerformanceN/AN/AN/A0.14%
1 Month Performance-5.87%-0.69%5.19%6.79%
1 Year Performance63.01%8.13%40.36%38.93%

Health Sciences Acquisitions Co. 2 Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HSAQ
Health Sciences Acquisitions Co. 2
N/A$4.01
-0.2%		N/A+65.7%$44.96MN/AN/A4
NSPR
InspireMD
3.1179 of 5 stars		$1.20
+5.3%		$5.00
+316.7%		-54.6%$56.27M$8.98MN/A50
TMDIF
Titan Medical
N/A$0.33
+2.3%		N/A+12.3%$37.63M$17.63MN/A50
PETV
PetVivo
N/A$0.80
+0.0%		N/A+26.7%$28.64M$1.05MN/A20
RVP
Retractable Technologies
N/A$0.63
+1.5%		N/A-7.0%$19.07M$38.27MN/A240

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HSAQ) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Why I flew on a tiny helicopter next to a potential nuclear bomb target
Satellite Confirms: Elon Musk Activating Strange 'Dark Energy' Across U.S. South Confirmed by satellites 30...
Altimetry | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel